GaBI Journal publishes four issues in 2013
Suggested evaluation of biological drugs role for WHO – Editor’s response
Do low- to middle-income countries need a biosimilar approval pathway based on a full comparability exercise?
Legislative efforts to limit prescription information sharing between patients and healthcare providers represent a serious threat to the health and safety of the American nation
Critical immunogenicity differences will be obscured by a common INN for biosimilars
WHO leadership in public safety on biosimilars to be commended
Biosimilars naming and prescribing policy in Australia
Maximizing quality in the manufacture of biologicals
Establishment of reference standards in biosimilar studies
Understanding the components of pharmaceutical expenditure—overview of pharmaceutical policies influencing expenditure across European countries
Immunogenicity of biosimilar monoclonal antibodies
Pathway to affordable, quality-assured sources of pegylated interferon alpha for treating hepatitis C
The authorization of non-biological complex drugs (NBCDs) follow-on versions: specific regulatory and interchangeability rules ahead?
Biosimilar development and regulation in Japan